Data availability Data is provided within the manuscript or supplementary information files
Glycocalyx degradation after cardiac arrest and resuscitation in rats induces vascular endothelial adhesion factor (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), iNOS, and COX-2 expression, exacerbating neuronal loss, glial activation, and brain edema
Tatem explains how peptides like GLP-1 drugs are transforming weight loss and metabolic health, while others such as BPC-157 and TB-500 accelerate healing and tissue repair

Key comparative insights from the benzimidazole class: All benzimidazoles share CYP450-dependent hepatic metabolism, creating a common vulnerability pathway Hepatotoxicity risk across the class is dose-dependent and duration-dependent consistent with the fenbendazole case reports Hepatotoxicity is generally reversible upon discontinuation across all benzimidazoles also consistent with fenbendazole data The mechanism appears to involve both direct metabolite toxicity and immune-mediated components, particularly when combined with immunomodulatory agents Veterinary safety data for fenbendazole shows remarkable tolerability: studies in dogs have documented safety margins of 100 the standard dose without significant hepatotoxicity, suggesting that the human cases represent an uncommon susceptibility pattern rather than inherent high toxicity This class-level perspective reinforces that fenbendazole's hepatotoxic risk is real but predictable, dose-related, and manageable with appropriate monitoring consistent with the safety profile of related compounds that have decades of human clinical use data
